These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 19585842)
1. [Follow up studies as a condition for drug subsidizing]. Kieler H; Ekbom A; Fored M; Montgomery SM; Wettermark B Lakartidningen; 2009 May 13-19; 106(20):1406-7. PubMed ID: 19585842 [No Abstract] [Full Text] [Related]
2. [Drug manufacturer on the savings package of Ulla Schmidt. "Grip in the moth box of planned economics"]. Schmidt K MMW Fortschr Med; 2001 Nov; 143(44):52. PubMed ID: 11732398 [No Abstract] [Full Text] [Related]
3. [Priorities by the board of drug benefits--guidelines clarify. Clinical trials are not sufficient for decisions on subsidizing]. Carlsson P Lakartidningen; 2003 Jul; 100(30-31):2428-9. PubMed ID: 12914137 [No Abstract] [Full Text] [Related]
4. Should the patent system for new medicines be abolished? DiMasi JA; Grabowski HG Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100 [No Abstract] [Full Text] [Related]
6. Drug therapy: safety, effectiveness, and economics. Brandys J Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340 [TBL] [Abstract][Full Text] [Related]
7. [Ranking the efficacy of drugs--a question of "class"? It is difficult to determine equivalency of two different treatments]. Liedholm H; Linné AB Lakartidningen; 2002 Sep; 99(36):3492-4, 3497-9, 3502. PubMed ID: 12362748 [TBL] [Abstract][Full Text] [Related]
8. [For the first time a health insurance company publishes drug data. Surprise: the thriftiest colleagues are in the East]. Schmidt K MMW Fortschr Med; 2001 Nov; 143(44):53. PubMed ID: 11732399 [No Abstract] [Full Text] [Related]
9. Payers struggle to ensure high level of adherence to costly specialty drugs. Sipkoff M Manag Care; 2008 Jul; 17(7):24-6, 29, 31. PubMed ID: 18757021 [No Abstract] [Full Text] [Related]
10. [Non-interventional studies give good follow-up possibilities. Increased demand both nationally and internationally can be predicted]. Strandberg K Lakartidningen; 2007 Sep 12-18; 104(37):2597-9. PubMed ID: 17970395 [No Abstract] [Full Text] [Related]
11. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ]. Soto Alvarez J Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442 [No Abstract] [Full Text] [Related]
12. Link cost to clinical outcome. Norris J BMJ; 2007 May; 334(7601):968. PubMed ID: 17493992 [No Abstract] [Full Text] [Related]
14. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective]. Lundin D; Carlsson P; Levin LA; Persson U Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321 [No Abstract] [Full Text] [Related]
15. [From the very valuable therapy, to the high cost of a new drug: a growing hiatus]. Scheen AJ Rev Med Suisse; 2005 Aug; 1(30):1931-2. PubMed ID: 16200935 [No Abstract] [Full Text] [Related]
16. [Important to keep the principle of value-based pricing of drugs]. Persson U; Levin LA; Pettersson B Lakartidningen; 2009 Oct 28-Nov 3; 106(44):2862-4. PubMed ID: 19967967 [No Abstract] [Full Text] [Related]
17. Hypertension control: improved, but not enough! Alderman MH Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338 [No Abstract] [Full Text] [Related]
18. Market watch: pricing strategies for emerging markets. Lineberry N; Snyder E; Gunda S Nat Rev Drug Discov; 2011 Aug; 10(8):567. PubMed ID: 21804586 [No Abstract] [Full Text] [Related]
19. Pharmaceuticals and medical devices: business practices. Jones TM Issue Brief Health Policy Track Serv; 2009 Jan; ():1-54. PubMed ID: 19297719 [No Abstract] [Full Text] [Related]
20. What's in a perspective? Glick HA Value Health; 2010; 13(1):2. PubMed ID: 19912594 [No Abstract] [Full Text] [Related] [Next] [New Search]